Verve Therapeutics Cash Flow Statement

Financials in millions EUR. Fiscal year is January - December.

Millions EUR. Fiscal year is Jan - Dec.

Fiscal Year	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020
Net Income	-2.27	-2.45	-0.57	-
Depreciation & Amortization	0.14	0.02	0.08	-
Other Amortization	1.12	1	-	-
Other Operating Activities	-0.1	0.25	-	-
Change in Accounts Receivable	0.02	0.11	-0.13	-
Change in Inventory	-0.03	-0.3	-0.14	-
Change in Accounts Payable	0.35	0.1	-0.02	-
Change in Unearned Revenue	0.01	-0.14	-0.02	-
Change in Other Net Operating Assets	-0.16	0.26	0.02	-
Operating Cash Flow	-0.91	-1.14	-0.78	-
Capital Expenditures	-	-0.01	-	-
Sale of Property, Plant & Equipment	0	-	-	-
Sale (Purchase) of Intangibles	-0.54	-0.86	-0.58	-
Investment in Securities	-0	-0.01	-0.06	-
Other Investing Activities	-0	-	-	-
Investing Cash Flow	-0.55	-0.88	-0.64	-
Short-Term Debt Issued	0.56	0.17	-	-
Long-Term Debt Issued	0.38	0.5	-	-
Total Debt Issued	0.93	0.67	-	-
Short-Term Debt Repaid	-	-	-0.08	-
Long-Term Debt Repaid	-0.04	-0.02	-0.04	-
Total Debt Repaid	-0.04	-0.02	-0.12	-
Net Debt Issued (Repaid)	0.89	0.65	-0.12	-
Issuance of Common Stock	0.47	-	3.03	-
Other Financing Activities	-0.04	-0.05	-0.01	-
Financing Cash Flow	1.37	0.6	2.9	-
Miscellaneous Cash Flow Adjustments	0	-0	0	-
Net Cash Flow	-0.08	-1.42	1.48	-
Free Cash Flow	-0.91	-1.15	-0.78	-
Free Cash Flow Margin	-203.81%	-186.27%	-143.99%	-
Free Cash Flow Per Share	-0.09	-0.12	-	-
Levered Free Cash Flow	-0.7	-1.39	-	-
Unlevered Free Cash Flow	-0.66	-1.38	-	-
Change in Working Capital	0.19	0.04	-0.29	-

Source: S&P Global Market Intelligence. Standard template. Financial Sources.